Gina Jiang has carved out a remarkable path in the world of biotechnology, emerging as one of Hong Kong’s leading figures in the development of advanced cancer therapies. Her journey has been anything but conventional. Born to an orthopaedic surgeon father and an
A new report from a US congressional commission has issued an urgent alert about China’s accelerating rise in the biotechnology field, calling the speed and scale of its progress “sobering, even frightening”. The National Security Commission on Emerging Biotechnology (NSCEB), which spent two
Suzhou, a city long celebrated for its classical gardens, ancient canals and poetic landscapes, is rapidly reinventing itself as one of China’s most ambitious biotechnology hubs. Five years ago, local leaders laid out a daring plan: transform Suzhou into the “Pharma Valley of
China’s biotechnology sector is entering a new phase of scientific acceleration as research laboratories expand their use of automated platforms for drug discovery. These systems combine robotics, artificial intelligence, high-throughput screening, and advanced data analysis tools to reduce the time required to identify
Funding in genomics and personalized medicine has become a key driver of innovation in China’s biotech sector. With the increasing application of genetic sequencing, precision therapeutics, and data-driven healthcare, financial support is crucial for research, development, and commercialization. Investment flows from government programs,
Collaboration between hospitals and biotech companies is accelerating medical innovation, improving patient care, and advancing therapeutic development in China. By combining clinical expertise with research and technological capabilities, these partnerships enable the translation of laboratory discoveries into practical healthcare solutions. This blog explores
China’s aging population presents both demographic challenges and economic opportunities. Biotech startups are increasingly focusing on developing solutions that address age-related diseases, mobility issues, cognitive decline, and preventive healthcare. These companies leverage genomics, regenerative medicine, AI-driven diagnostics, and personalized therapeutics to improve the
CRISPR-Cas9 technology has revolutionized genetic research, enabling precise editing of DNA sequences in living organisms. Chinese biotech labs have emerged as leaders in CRISPR applications, advancing research in disease treatment, agriculture, and therapeutic innovation. While CRISPR offers immense potential, it raises ethical questions
China’s biotech sector is making significant strides in addressing rare diseases through research, innovation, and advanced laboratory techniques. Rare diseases, often genetic in origin, affect a small percentage of the population but present complex challenges for diagnosis, treatment, and drug development. Chinese biotech
China’s National Medical Products Administration (NMPA) has released new guidelines for the development and deployment of AI-powered healthcare devices, aiming to ensure safety, efficacy, and regulatory compliance in hospitals and medical facilities nationwide. The guidance covers AI-based diagnostic tools, wearable health monitors, and
